Previous 10 | Next 10 |
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete i...
2024-05-14 13:39:08 ET Ocugen, Inc. (OCGN) Q1 2024 Earnings Conference Call May 14, 2024, 8:30 am ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, CEO & Co-Founder Michael Breininger - Corporate Controller...
2024-05-14 08:02:08 ET More on Ocugen Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen Q1 2024 Earnings Preview Ocugen stock jumps after $175M securiti...
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets MALVERN, Pa., May 14, 2024 (GLOBE ...
2024-05-13 12:08:33 ET More on Ocugen Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen stock jumps after $175M securities filing Ocugen says EU backs a...
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that its Board of Directors declared a dividend of one on...
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri...
2024-05-07 09:51:20 ET Ocugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes that OCU400 will be approved by the Food and Drug Administration (FDA). The stock surged by over 378% from its lowest point in September and by 183% this year. OC...
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to d...
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...